Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated November 12, 2024, discloses insider trading activities in compliance with Article 19 of Regulation No. 596/2014 on market abuse. The report details transactions executed on November 11, 2024, by David Moore, Executive Vice President and Head of Corporate Development.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is strictly a regulatory disclosure of share transactions.
Material Changes and Transaction Details
The filing reports two distinct transactions involving Novo Nordisk B shares (ISIN: DK0062498333) by David Moore on November 11, 2024:
- Acquisition: 18,634 shares acquired at a price of DKK 0.00 per share. This transaction was executed outside a trading venue as part of a recruitment package.
- Sale: 9,919 shares sold at a price of DKK 759.96 per share. This transaction was executed on Nasdaq Copenhagen, resulting in an aggregated value of DKK 7,538,047.37.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, risk factors, or discussion of contingencies. It includes a standard corporate overview stating that Novo Nordisk is a global healthcare company founded in 1923, employing approximately 72,000 people across 80 countries, with a focus on defeating serious chronic diseases.
Key Facts for Investor Verification
- Verify the total net change in share ownership for David Moore (18,634 acquired vs. 9,919 sold).
- Confirm the nature of the zero-cost acquisition as a recruitment package benefit.
- Note the sale price of DKK 759.96 per share as a market reference point for November 11, 2024.
- Recognize that this document does not reflect the company's quarterly or annual financial results.